Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 17 companies, including Deshi Biotech, regarding their overseas listing applications [1] - Deshi Biotech submitted its listing application to the Hong Kong Stock Exchange on June 29, 2025, with Huatai International as the sole sponsor [1] - The CSRC requires Deshi Biotech to clarify its business scope and whether it involves any foreign investment restrictions, particularly in areas like human stem cells and gene diagnosis and treatment [1][2] Group 2 - Deshi Biotech's iMedImage is recognized as the world's largest general medical imaging base model and has achieved commercialization [2] - The iMedImage model supports 19 types of medical imaging modalities and covers over 90% of clinical medical imaging scenarios, including reproductive health and hematological malignancies [2] - The solutions provided by iMedImage significantly reduce R&D costs and time to market, addressing uneven distribution of medical resources and improving diagnostic efficiency [2]
新股消息 | 德适生物拟港股上市 中国证监会要求说明上市前后个人信息保护和数据安全的安排或措施
智通财经网·2025-08-08 11:45